NCT05495750

Brief Summary

the aim is to determine the value of adding bilateral supra zygomatic maxillary nerve block to general anesthesia in attenuating the systemic inflammatory response in paediatrics.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jun 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 24, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 9, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 10, 2022

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 5, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 25, 2024

Completed
Last Updated

February 28, 2024

Status Verified

February 1, 2024

Enrollment Period

1.5 years

First QC Date

August 9, 2022

Last Update Submit

February 26, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Interleukin 6 serum level.

    Two blood samples will be withdrawn in both groups, the first sample immediately after induction of general anaesthesia, endotracheal tube insertion and the other sample will be withdrawn after completion of surgery and before recovery of the patient

    3-5 hours

Secondary Outcomes (8)

  • Serum Cortisol level

    3-5 hours

  • Plasma glucose level

    3-5 hours

  • C-Reactive protein (CRP)

    3-5 hours

  • Total leucocytic count

    3-5 hours

  • CHIPPS score

    1 hour (h), 2 h, 4 h, 6 h, 8 h, 12 h postoperatively.

  • +3 more secondary outcomes

Study Arms (2)

Maxillary block group

ACTIVE COMPARATOR

The ultrasound probe will be placed in the infra zygomatic area, with an inclination of 45 degrees in the transverse plane. A 27-gauge 38-mm needle will be used for the injection. The needle will be inserted perpendicular to the skin at the frontozygomatic angle and advanced to the greater wing of the sphenoid. The needle will be then redirected and advanced to the pterygopalatine fossa. Loss of resistance after passing through the temporalis muscle will assist in determining the puncture depth, and real-time ultrasound guidance will allow seeing the spread of local anesthetic in the pterygopalatine fossa.

Drug: Bupivacaine 0.25% Injectable Solution

Control group

NO INTERVENTION

Patients will receive only general anesthesia with regulated doses of IV opioids.

Interventions

ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg.

Also known as: supra zygomatic maxillary nerve block
Maxillary block group

Eligibility Criteria

Age1 Year - 5 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Primary and secondary cleft palate Surgeries.
  • American Society of Anesthesiologists physical status (ASA) I to II patients.
  • Age group: 1-5 years old.

You may not qualify if:

  • Presence of coagulation disorders.
  • Peripheral neuropathy.
  • Local infection or lesion in puncture site.
  • Allergy to local Anesthetics.
  • Physical status: ASA III or above.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of dentisry Ainshams univeristy

Cairo, Egypt

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Bupivacaine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Sherif S Sultan, MD

    Ainshams University

    STUDY DIRECTOR
  • Tamer N Ibrahim AbdelRahman, MD

    Ainshams Univeristy

    STUDY CHAIR
  • Sohib M Galal, MD

    Ainshams Univeristy

    STUDY CHAIR
  • Sarah A Salem, MD

    Ainshams Univeristy

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Lecturer

Study Record Dates

First Submitted

August 9, 2022

First Posted

August 10, 2022

Study Start

June 24, 2022

Primary Completion

January 5, 2024

Study Completion

February 25, 2024

Last Updated

February 28, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will share

Summary results

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
6 months after publication
Access Criteria
Internet search by keywords

Locations